Wnt/β‐catenin–mTOR crosstalk in TSC-associated epilepsy: pharmacological evidence and therapeutic opportunities
Frontiers in Pharmacology · 05.11.2026 · 17
DOI: 10.3389/fphar.2026.1972918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.11.2026. Verfasst von Roaya S. Alqurashi. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tuberous sclerosis complex (TSC), caused by pathogenic variants in TSC1 or TSC2 , is frequently associated with early-onset and drug-resistant epilepsy. Loss of hamartin–tuberin activity causes Rheb-dependent mTORC1 hyperactivation and provides the mechanistic basis for mTOR-directed treatment with everolimus, but mTORC1 activation alone does not fully account for variation in seizure burden or treatment response. Evidence from biochemical and disease-model studies indicates that TSC1/TSC2 also interacts with canonical Wnt/β-catenin signaling through GSK3β and Axin, while cellular metabolism may provide an additional point of convergence through AMPK-dependent regulation of TSC2. This narrative review examines the biochemical, neuronal, human-tissue, pharmacological, and clinical evidence for this Wnt–GSK3β–TSC2–mTOR framework and distinguishes established findings from context-limited, emerging, and hypothetical relationships. Everolimus remains the established mechanism-based therapy for TSC-associated refractory seizures, whereas metformin has the strongest TSC-specific clinical signal among the investigational metabolic approaches discussed. GLP-1 receptor agonists and direct GSK3β modulation remain preclinical or mechanistically speculative in this setting. Gene- and RNA-based approaches provide emerging precedents for pathway-selective intervention, but none has directly targeted the Wnt–GSK3β–TSC2 interface. The principal unresolved question is whether this signaling relationship operates in human TSC epileptogenic tissue. Direct tissue-level validation, followed by selective pathway interrogation and adequately powered therapeutic studies, is needed before Wnt-directed strategies can be considered clinically relevant in TSC-associated epilepsy.
Zitieren
APA
Alqurashi, R. S. (2026). Wnt/β‐catenin–mTOR crosstalk in TSC-associated epilepsy: pharmacological evidence and therapeutic opportunities. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1972918
Vancouver
Alqurashi RS. Wnt/β‐catenin–mTOR crosstalk in TSC-associated epilepsy: pharmacological evidence and therapeutic opportunities. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1972918
BibTeX
@article{Alqurashi2026,
author = {Alqurashi, Roaya S.},
title = {Wnt/β‐catenin–mTOR crosstalk in TSC-associated epilepsy: pharmacological evidence and therapeutic opportunities},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1972918}
}
EUVIMED